Introgen transfers listing to Nasdaq Capital Market from Nasdaq Global Market.

martes, 3 de marzo de 2026, 2:12 am ET1 min de lectura
INGN--

Introgen Therapeutics, a biotech company, announced that its common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective November 19, 2008. The company's shares will continue to trade under the ticker "INGN" and must demonstrate compliance with all listing requirements of the Nasdaq Capital Market by March 3, 2009.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios